For the year ending 2025-12-31, RCUS has $1,139M in assets. $222M in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 222 | |||
| Marketable securities | 759 | |||
| Receivable from collaboration partners ( and 6 from a related party) | 11 | |||
| Prepaid expenses and other current assets | 15 | |||
| Total current assets | 1,007 | |||
| Long-term marketable securities | 29 | |||
| Property and equipment, net | 40 | |||
| Other noncurrent assets | 63 | |||
| Total assets | 1,139 | |||
| Accounts payable (24 and to a related party) | 42 | |||
| Deferred revenue (35 and 85 to a related party) | 35 | |||
| Other current liabilities | 154 | |||
| Total current liabilities | 231 | |||
| Deferred revenue, noncurrent (43 and 234 to a related party) | 43 | |||
| Long-term debt | 99 | |||
| Other noncurrent liabilities | 135 | |||
| Common stock and additional paid-in capital 0.0001 par value per share 400.0 shares authorized 125.3 shares in 2025 and 92.2 shares in 2024 issued and outstanding | 2,116 | |||
| Accumulated deficit | -1,485 | |||
| Total stockholders equity | 631 | |||
| Total liabilities and stockholders equity | 1,139 | |||
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)